Venclexta degrades malignant lymphocytes by binding and inhibiting the BCL-2 protein. Venclexta is used in the treatment of chronic lymphocytic leukemia with a 17p deletion mutation. So what should patients pay attention to when using Venclexta?

Ribomustin is also known by other common names such as Treanda, Treakisym, a chemotherapy drug used in the treatment of multiple myeloma, chronic leukemia and non-Hodgkin lymphoma.

Leukemia occurs when there are mutations or other changes in the DNA genes of blood cells. This causes cells to grow and divide faster, invading healthy cells. When red blood cells and platelets are destroyed in large numbers, disease symptoms will appear.